证券代码：688289 证券简称：圣湘生物 公告编号：2025-056 人博卡病毒（HBoV）和人偏肺病毒（HMPV）均为近年来备受关注的常见呼吸 道病毒之一，可引起急性呼吸道感染，尤其对 5 岁以下儿童和老年群体构成较大危害。 二者感染症状与流感、腺病毒、合胞病毒等其他呼吸道病原体高度相似，且混合感染 比例居高，临床表现可能从无症状、轻微感冒样症状到支气管炎、肺炎、哮喘急性发 作甚至危及生命，因此，亟需高效精准的检测方法予以快速鉴别，为临床精准诊断与 治疗决策提供循证依据。 公司本次获证的人博卡病毒、人偏肺病毒核酸检测试剂盒，基于多重荧光 PCR 技术，可实现对两种病原体的高灵敏度、高特异性检测，结合公司现有的呼吸道感染 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的产品人博卡病毒、 人偏肺病毒核酸检测试剂盒（荧光 PCR 法）于近日收到由国家药品监督管理局颁发 的《医疗器械注册证》，现将相关情况公告如下： 一、产品注册相关情况 | 注册人名称 | 圣湘生物科 ...

Core Viewpoint - The scientific instrument industry has seen a resurgence in mergers and acquisitions (M&A), with 31 transactions totaling over 220.6 billion yuan as of August 11, 2025, indicating a trend of "reduced volume but increased value" compared to the previous year [1][2]. Summary by Sections M&A Activity Overview - As of August 11, 2025, the scientific instrument industry recorded 31 M&A transactions with a total disclosed value exceeding 220.6 billion yuan, with the highest single transaction amounting to 125.4 billion yuan [2]. - In comparison, the previous year saw 39 transactions with a total value of only 53.4 billion yuan, highlighting a significant increase in transaction value in 2025 [2]. Strategic Focus of M&A - Unlike the previous year where Brook dominated with high-frequency acquisitions, 2025 has seen major players like Waters, bioMérieux, and Saint Shining Biotech each completing two transactions, focusing on technology integration and market expansion [2][3]. - The majority of M&A activities are concentrated in the life sciences sector, accounting for 78% of total transactions, while semiconductor measurement and optoelectronic sensing sectors saw a decline in activity [3]. Notable Transactions - Waters initiated a significant acquisition of BD's biosciences and diagnostics business for 17.5 billion USD (approximately 125.4 billion yuan), positioning it as a transformative move aimed at achieving substantial value growth through synergies [4]. - Siemens acquired Dotmatics, a life sciences software company, for 5.1 billion USD, enhancing its competitive edge in medical technology [4]. - Thermo Fisher's acquisition of Solventum for 4.1 billion USD fills a critical gap in purification and filtration technology, aiming to capture growth in the biopharmaceutical market [5]. Domestic M&A Trends - Domestic companies like Saint Shining Biotech and Crystal Technology have also been active, with each completing two acquisitions, although the total amounts are significantly lower than those of foreign firms [6]. - The trend of acquiring overseas companies is evident, as seen with Titan Technology's acquisition of the UK-based biochemical reagent brand Apollo Scientific, aimed at expanding its global market presence [9]. Strategic Implications - The M&A landscape reflects a shift towards cross-industry acquisitions as companies seek new growth avenues, supported by favorable policies from regulatory bodies [8]. - Companies are increasingly focusing on core business areas while divesting slower-growing segments to streamline operations and enhance strategic precision [8]. - The integration of global channels and technology through acquisitions is becoming essential for domestic firms to compete internationally [11].

Core Viewpoint - Shengxiang Biotechnology Co., Ltd. is experiencing a decline in stock price while maintaining a competitive position in the medical device industry, with significant growth in revenue and net profit reported in the latest quarterly results [1][2]. Company Overview - Shengxiang Biotechnology focuses on innovative gene technology, providing integrated solutions for in vitro diagnostics, including diagnostic reagents, instruments, and third-party medical testing services [2]. - The company has achieved notable recognition, ranking in the top 100 global medical device companies for two consecutive years and receiving various national and provincial honors [2]. Financial Performance - For Q1 2025, the company reported revenue of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, up 13.22%, with a gross profit margin of 76.71% [2]. Market Position - As of August 14, the company's stock closed at 21.64 yuan, with a rolling PE ratio of 43.79, compared to the industry average of 55.76 and a median of 39.14 [1][3]. - The total market capitalization of Shengxiang Biotechnology is 12.538 billion yuan [1]. Shareholder Information - As of March 31, 2025, the number of shareholders increased to 20,629, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1].

随着中报披露的结束，市场已将目光转向三季报业绩预告。 进一步梳理可见，在上述三季报业绩预喜的公司中，有86家公司净利润同比有望翻番。其中，北新建 材、圣湘生物、达安基因、好想你、星网宇达、康泰医学、海联金汇等7家公司预计三季报净利润同比 增幅上限均在10倍以上。 对此，粤开证券认为，从已披露的500余家上市公司三季报业绩预告情况来看，目前创业板、中小板企 业的预喜率相对高于主板。以业绩预告均值测算，三季度净利润增速在20%以上公司占比较大的行业， 主要包括医药生物、化工、电子等。进一步结合估值来看，目前估值水平较低的行业，包括家用电器、 化工和轻工制造行业等。(张颖) 《证券日报》根据同花顺统计发现，截至9月18日9：00，沪深两市共有538家上市公司发布2020年三季 报业绩预告，其中，预喜公司数量达199家(含预增、略增、扭亏、续盈)，占比37%。 ...

通过天眼查大数据分析，圣湘生物科技股份有限公司共对外投资了27家企业，参与招投标项目1057次， 知识产权方面有商标信息387条，专利信息467条，此外企业还拥有行政许可311个。 资金流向方面，今日主力资金净流出2072.15万元，占比成交额10.57%。其中，超大单净流出1542.93万 元、占成交额7.87%，大单净流出529.22万元、占成交额2.7%，中单净流出流出1058.03万元、占成交额 5.4%，小单净流入3130.18万元、占成交额15.96%。 圣湘生物最新一期业绩显示，截至2025一季报，公司营业总收入4.75亿元、同比增长21.62%，归属净利 润9173.55万元，同比增长13.22%，扣非净利润9049.78万元，同比增长22.70%，流动比率4.439、速动比 率4.159、资产负债率23.25%。 天眼查商业履历信息显示，圣湘生物科技股份有限公司，成立于2008年，位于长沙市，是一家以从事医 药制造业为主的企业。企业注册资本57938.8006万人民币，实缴资本12648.8642万人民币。公司法定代 表人为戴立忠。 金融界消息 截至2025年8月11日收盘，圣湘生物（688 ...

Group 1 - The core business of the company is to provide integrated in vitro diagnostic solutions centered on self-innovated gene technology, including diagnostic reagents, instruments, and third-party medical testing services [2] - The company has significantly improved its brand recognition and industry position, receiving high recognition and honors from authoritative institutions both domestically and internationally [2] - The latest performance report for Q1 2025 shows the company achieved an operating income of 475 million yuan, a year-on-year increase of 21.62%, and a net profit of 91.73 million yuan, a year-on-year increase of 13.22%, with a gross profit margin of 76.71% [2] Group 2 - As of August 8, the company's stock closed at 21.78 yuan, down 1.94%, with a rolling price-to-earnings (PE) ratio of 44.08 times and a total market value of 12.619 billion yuan [1] - The average PE ratio for the medical device industry is 55.70 times, with a median of 39.08 times, placing the company at the 82nd position in the industry ranking [1][3] - As of Q1 2025, three institutions held shares in the company, with a total of 359,800 shares valued at 0.07 million yuan [1]

Financial Performance - As of the first quarter of 2025, the company reported total revenue of 475 million yuan, representing a year-on-year growth of 21.62% [1] - The net profit attributable to shareholders was 91.73 million yuan, an increase of 13.22% year-on-year [1] - The non-recurring net profit was 90.50 million yuan, showing a year-on-year growth of 22.70% [1] - The current ratio stood at 4.439, and the quick ratio was 4.159, indicating strong liquidity [1] - The debt-to-asset ratio was 23.25%, reflecting a low level of financial leverage [1] Stock Performance - As of August 8, 2025, the stock price closed at 21.78 yuan, down 1.94% [1] - The turnover rate was 1.73%, with a trading volume of 100,300 lots and a transaction amount of 221 million yuan [1] - There was a net outflow of main funds amounting to 15.86 million yuan, accounting for 7.19% of the transaction amount [1] Investment and Intellectual Property - The company has made investments in 27 enterprises and participated in 1,054 bidding projects [2] - It holds 387 trademark registrations and 467 patent applications, indicating a strong focus on intellectual property [2] - The company has obtained 311 administrative licenses, showcasing its compliance and operational capabilities [2] Company Overview - Established in 2008, the company is located in Changsha and primarily engages in the pharmaceutical manufacturing industry [1] - The registered capital is approximately 5.79 billion yuan, with paid-in capital of about 1.26 billion yuan [1] - The legal representative of the company is Dai Lizhong [1]

尖山名片 尖山位于长沙信息产业园内，三峰相连，最高峰240.2米；山脚下的尖山湖，取尖山之灵气、占麓谷之风水，湖 因山而得名，山因湖而更具灵气；作为现代景观的尖山湖公园，更是山水相依、浑然天成。"尖山云气来衡岳， 鱼波流水下洞庭"，此情此景令人流连忘返。 长沙晚报全媒体记者 周斌 明《一统志》载："尖山在府城距湘东十五里，巍然一峰秀出天表，亦名圭峰。山呈锥形，山峰尖耸，峰小而 锐，因以得名。"这一记载道出了尖山名字的由来。 "尖山尖得恶，顶不了谷山一个角！"这是走读团成员、尖山下长大的退休教师雷万里与大家探山时作的开场 白。谷山和尖山，相距不远，然而在当地，尖山的名气似乎更胜一筹，可见其独特魅力。作为长沙近郊山峰， 尖山见证着星城近年发展的同时，自己也飞速发展：从一个人烟寥落的小山村，到周边高楼林立的现代化产业 新城。 山巅曾是长沙城乡分界岭 8月1日清晨，走读团一行驾车从长沙晚报社出发西行，上岳麓大道，半小时左右就到了位于湖南湘江新区腹地 的尖山脚下。 远望尖山，三座山峰紧密相连，宛如骆驼背上的驼峰，又如耸入云端的笔架，如果没有雷万里的"解说"，走读 团成员会把它们当成一座山头。 6年前从长沙高新区虹桥小学 ...

报告目录 【全新修订】：2025年8月 【出版机构】：中智信投研究网 全球与中国蛋白质定量检测试剂盒市场发展趋势及前景预测分析报告2025～2031年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 1 蛋白质定量检测试剂盒市场概述 1.1 产品定义及统计范围 1.2 按照不同比色法类，蛋白质定量检测试剂盒主要可以分为如下几个类别 1.2.1 全球不同比色法类蛋白质定量检测试剂盒销售额增长趋势2020 VS 2024 VS 2031 1.2.2 BCA 1.2.3 Bradford 1.2.4 Lowry 1.2.5 UV 1.3 从不同应用，蛋白质定量检测试剂盒主要包括如下几个方面 1.3.1 全球不同应用蛋白质定量检测试剂盒销售额增长趋势2020 VS 2024 VS 2031 1.3.2 大学 2.1.1 全球蛋白质定量检测试剂盒产能、产量、产能利用率及发展趋势（2020-2031） 1.3.3 研究中心 1.3.4 其他 2.1.2 全球蛋白质定量检测试剂盒产量、需求量及发展趋势（2020-2031） 1.4 蛋白质定量检测试剂盒 ...

Group 1: Epidemic Overview - The recent outbreak of Chikungunya fever in southern China has led to nearly 3,000 new cases reported in just one week, primarily in Guangdong province, affecting over ten cities [1][3] - The majority of cases are concentrated in Foshan, accounting for 95% of the total cases in Guangdong, with no severe cases or deaths reported so far [3] Group 2: Government Response and Guidelines - The National Health Commission has released the "Chikungunya Fever Diagnosis and Treatment Plan (2025 Edition)," emphasizing that the disease is preventable, controllable, and treatable [3][6] - The plan incorporates traditional Chinese medicine (TCM) approaches, highlighting the role of TCM in alleviating symptoms and promoting recovery [6] Group 3: Company Initiatives in Diagnostics and Treatment - Several listed companies in the IVD (in vitro diagnostics) sector are actively developing testing products and treatment solutions for Chikungunya fever [4][5] - Shenzhen BGI Technology Co., Ltd. has introduced the T1+ gene sequencer, which can provide comprehensive genomic analysis within 6-8 hours, aiding in rapid response to the outbreak [4] - Wanfu Biology has developed multiple Chikungunya virus detection products, creating a closed-loop system for monitoring and diagnosis [4] Group 4: Traditional Chinese Medicine Applications - TCM is being utilized for symptomatic treatment of Chikungunya fever, with specific formulations recommended for managing symptoms like fever and joint pain [6][7] - Companies such as Guangdong Yifang Pharmaceutical and Step Long Pharmaceutical are producing traditional Chinese medicines that may assist in treating Chikungunya fever [7]